Multi-Modality Quantitative Imaging for Evaluation of Response to Cancer Therapy

用于评估癌症治疗反应的多模态定量成像

基本信息

批准号：
10437852
负责人：
Yong Du
金额：
$ 64.24万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-19 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10437852
关键词：
Adopted Adoption Advanced Malignant Neoplasm Algorithms Alkaline Phosphatase Area Bone neoplasms Clinical Clinical Trials Data Development Evaluation FOLH1 gene Financial compensation Goals Gold Grant Human Image Image Analysis Imaging Device Institution Lesion Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of prostate Measures Metastatic Neoplasm to the Bone Methods Minor Noise PET/CT scan Patients Positron-Emission Tomography Prevalence Prostate Adenocarcinoma Prostate Cancer therapy Prostate-Specific Antigen Protocols documentation Radionuclide Imaging Regimen Serum Markers Software Tools Source System Technetium Tc 99m Medronate Techniques Testing Time Translating Tumor Burden Tumor Volume Vendor Visual advanced disease anatomic imaging anticancer research automated segmentation base bone bone imaging cancer therapy castration resistant prostate cancer clinical practice cost imaging biomarker imaging modality imaging study improved in vivo indexing interest multimodality new therapeutic target novel therapeutics predicting response quantitative imaging quantum reconstruction relative cost response simulation single photon emission computed tomography standard of care targeted treatment treatment response trial comparing uptake

项目摘要

Bone metastases are common in advanced cancers including prostate adenocarcinoma, where there is evidence of bone metastases in more than 70% of patients with advanced disease. Despite their prevalence and the important clinical implications, there is currently no widely accepted quantitative imaging assessment for response to therapy. Assessment of response or progression is typically made based on visual interpretation of bone scintigraphy in conjunction with CT and serum markers. The goal of this project is thus to develop, validate, and advance to clinical practice multi-modality quantitative metrics for assessing response of bone metastases to therapy. Combined SPECT-CT systems and the implementation of robust compensation methods has enabled the development of quantitative SPECT imaging methods, which have recently become clinically available. Here we propose to exploit the nexus of these developments via the following 3 aims. (1) Using simulation and phantom studies, we will first optimize and evaluate methods for quantitative SPECT/CT (QSPECT) imaging of Tc-99m MDP. We propose to expand the phantom studies to a QIN cooperative project in order to evaluate the methods across different scanners and centers. (2) Based on these QSPECT methods, we will develop, optimize, and characterize quantitative bone SPECT indices for assessing response to therapy. Computing these indices will involve semi-automatic segmentation of bone and bone lesions, implemented in an integrated software tool. The indices calculated will include the number of lesions, bone lesion burden, and change in lesion uptake with therapy. We will characterize the variability of the indices using realistic simulations and in pre-therapy test-retest studies. (3) Finally, we will apply the methods and validate them in current clinical trials of new therapeutic regimens for bone metastatic castrate-resistant prostate cancer. In these studies, we will evaluate the methods in terms of time to progression and will compare the methods in vivo to similar quantitative metrics estimated from Na18F PET/CT. We will also investigate the amount of additional information provided by whole-body MRI and PSMA PET/CT. We will make the methods and images available to the QIN and propose to organize challenges of segmentation and response metrics to take advantage of the QIN-wide interest in these areas. Together, these quantitative imaging tools and studies will provide a validated approach for quantitative imaging-based evaluation of response in bone metastases that is readily clinically implementable with only a minor increase in cost relative to clinical standard bone scintigraphy.

骨转移在包括前列腺腺癌在内的晚期癌症中很常见，其中超过 70% 的晚期疾病患者存在骨转移的证据。尽管它们很流行以及重要的临床意义，目前还没有广泛接受的定量成像评估对治疗的反应。反应或进展的评估通常基于结合 CT 和血清标记物进行骨闪烁扫描的视觉解释。该项目的目标因此，我们的目标是开发、验证并推进临床实践的多模态定量指标来评估骨转移对治疗的反应。结合 SPECT-CT 系统和稳健的实施补偿方法促进了定量 SPECT 成像方法的发展，最近已进入临床。在这里，我们建议通过以下方式利用这些发展的联系：以下3个目标。 (1) 通过模拟和模型研究，我们将首先优化和评估方法 Tc-99m MDP 的定量 SPECT/CT (QSPECT) 成像。我们建议将模型研究扩展到 QIN 合作项目，旨在评估不同扫描仪和中心的方法。 (2) 基于这些 QSPECT 方法，我们将开发、优化和表征定量骨 SPECT 评估治疗反应的指标。计算这些指数将涉及半自动骨和骨病变的分割，在集成软件工具中实现。计算出的指数将包括病变数量、骨病变负荷以及治疗后病变摄取的变化。我们将使用现实模拟和治疗前重测研究来表征指数的变异性。 (3) 最后，我们将应用这些方法并在当前新治疗方案的临床试验中进行验证骨转移性去势抵抗性前列腺癌。在这些研究中，我们将根据以下方面评估这些方法进展时间，并将体内方法与估计的类似定量指标进行比较 Na18F PET/CT。我们还将调查全身 MRI 提供的附加信息量和 PSMA PET/CT。我们将向 QIN 提供方法和图像，并建议组织细分和响应指标的挑战，以利用 QIN 对这些的广泛兴趣地区。总之，这些定量成像工具和研究将为基于定量成像的骨转移反应评估，易于临床应用相对于临床标准骨闪烁扫描，成本仅略有增加即可实施。

项目成果

期刊论文数量（21）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Trainable high resolution melt curve machine learning classifier for large-scale reliable genotyping of sequence variants.

可训练的高分辨率熔解曲线机器学习分类器，用于序列变异的大规模可靠基因分型。

DOI：
发表时间：
2014
期刊：
影响因子：
3.7
作者：
Athamanolap, Pornpat;Parekh, Vishwa;Fraley, Stephanie I;Agarwal, Vatsal;Shin, Dong J;Jacobs, Michael A;Wang, Tza;Yang, Samuel
通讯作者：
Yang, Samuel

Noise considerations for PET quantification using maximum and peak standardized uptake value.

使用最大和峰值标准化摄取值进行 PET 定量时的噪声考虑因素。

DOI：
发表时间：
2012-07
期刊：
影响因子：
0
作者：
Lodge, Martin A;Chaudhry, Muhammad A;Wahl, Richard L
通讯作者：
Wahl, Richard L

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.

FLT 与 FDG PET/CT 在 IB-IIIA 期可切除 NSCLC 化疗反应早期评估中的比较。

DOI：
发表时间：
2017-12
期刊：
影响因子：
3.2
作者：
Crandall, John P;Tahari, Abdel K;Juergens, Rosalyn A;Brahmer, Julie R;Rudin, Charles M;Esposito, Giuseppe;Subramaniam, Deepa S;Knopp, Michael V;Hall, Nathan C;Gajwani, Prateek;Leal, Jeffrey P;Lodge, Martin A;O, Joo H;Gabrielson, Edward W;Sha
通讯作者：
Sha

Factors affecting the repeatability of gamma camera calibration for quantitative imaging applications using a sealed source.

影响使用密封源的定量成像应用的伽马相机校准可重复性的因素。